Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyButabarbital
Identification
- Name
- Butabarbital
- Accession Number
- DB00237 (APRD00752)
- Type
- Small Molecule
- Groups
- Approved, Illicit
- Description
Butabarbital (trade name Butisol) is a prescription barbiturate sleep aid. Butabarbital has a particularly fast onset of effects and short duration of action compared to other barbiturates, which makes it useful for certain applications such as treating severe insomnia and relieving anxiety before surgical procedures; however it is also relatively dangerous particularly when combined with alcohol, and so is now rarely used, although it is still prescribed in some Eastern European and South American countries. Its short duration of action gives butabarbital a high abuse potential, comparable to secobarbital. [Wikipedia]
- Structure
Structure for DB00237 (Butabarbital)
- Synonyms
- 5-Ethyl-5-(1-methylpropyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
- 5-Ethyl-5-(1-methylpropyl)barbituric acid
- 5-Sec-butyl-5-ethyl-2,4,6(1H,3H,5H)-pyrimidinetrione
- 5-Sec-butyl-5-ethylbarbituric acid
- 5-Sec-butyl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione
- Butabarbital
- Secbutabarbital
- Product Ingredients
Ingredient UNII CAS InChI Key Butabarbital Sodium 9WTD50I918 143-81-7 QORQZMBCPRBCAB-UHFFFAOYSA-M - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Butisol Sodium Tablet 30 mg/1 Oral Meda Pharmaceuticals Ltd 1939-08-01 Not applicable US 
Butisol Sodium Tab 100mg Tablet 100 mg Oral Carter Horner Corp. 1982-12-31 2001-01-02 Canada 
Butisol Sodium Tab 15mg Tablet 15 mg Oral Carter Horner Corp. 1982-12-31 2001-01-02 Canada Butisol Sodium Tab 30mg Tablet 30 mg Oral Carter Horner Corp. 1982-12-31 2001-01-02 Canada - International/Other Brands
- Butalan / Butisol / Sarisol No. 2
- Categories
- UNII
- P0078O25A9
- CAS number
- 125-40-6
- Weight
- Average: 212.2456
Monoisotopic: 212.116092388 - Chemical Formula
- C10H16N2O3
- InChI Key
- ZRIHAIZYIMGOAB-UHFFFAOYSA-N
- InChI
- InChI=1S/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)
- IUPAC Name
- 5-(butan-2-yl)-5-ethyl-1,3-diazinane-2,4,6-trione
- SMILES
- CCC(C)C1(CC)C(=O)NC(=O)NC1=O
Pharmacology
- Indication
For short-term treatment of insomnia and anxiety disorders
- Structured Indications
- Pharmacodynamics
Butabarbital, a barbiturate, is used for the treatment of short term insomnia. It belongs to a group of medicines called central nervous system (CNS) depressants that induce drowsiness and relieve tension or nervousness. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.
- Mechanism of action
Butabarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. All of these effects are associated with marked decreases in GABA-sensitive neuronal calcium conductance (gCa). The net result of barbiturate action is acute potentiation of inhibitory GABAergic tone. Barbiturates also act through potent (if less well characterized) and direct inhibition of excitatory AMPA-type glutamate receptors, resulting in a profound suppression of glutamatergic neurotransmission.
Target Actions Organism AGABA-A receptor (anion channel) positive allosteric modulatorHuman UNeuronal acetylcholine receptor subunit alpha-4 antagonistHuman UNeuronal acetylcholine receptor subunit alpha-7 antagonistHuman UGlutamate receptor 2 antagonistHuman UGlutamate receptor ionotropic, kainate 2 antagonistHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
Barbiturates are metabolized primarily by the hepatic microsomal enzyme system, and most metabolic products are excreted in the urine.
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
Signs of overdose include confusion (severe), decrease in or loss of reflexes, drowsiness (severe), fever, irritability (continuing), low body temperature, poor judgment, shortness of breath or slow or troubled breathing, slow heartbeat, slurred speech, staggering, trouble in sleeping, unusual movements of the eyes, weakness (severe).
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 7-Nitroindazole The risk or severity of adverse effects can be increased when Butabarbital is combined with 7-Nitroindazole. Experimental Acepromazine The risk or severity of adverse effects can be increased when Butabarbital is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Butabarbital is combined with Aceprometazine. Approved Adipiplon The risk or severity of adverse effects can be increased when Butabarbital is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Butabarbital is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Butabarbital is combined with Alaproclate. Experimental Alfaxalone The risk or severity of adverse effects can be increased when Butabarbital is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Butabarbital is combined with Alfentanil. Approved, Illicit Allopregnanolone The risk or severity of adverse effects can be increased when Butabarbital is combined with Allopregnanolone. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Butabarbital is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Butabarbital is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Butabarbital is combined with Alprazolam. Approved, Illicit, Investigational Amisulpride The risk or severity of adverse effects can be increased when Butabarbital is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Butabarbital is combined with Amitriptyline. Approved Amobarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Amobarbital. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Butabarbital is combined with Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Butabarbital is combined with Amperozide. Experimental Aripiprazole The risk or severity of adverse effects can be increased when Butabarbital is combined with Aripiprazole. Approved, Investigational Articaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Articaine. Approved Asenapine The risk or severity of adverse effects can be increased when Butabarbital is combined with Asenapine. Approved Azaperone The risk or severity of adverse effects can be increased when Butabarbital is combined with Azaperone. Investigational, Vet Approved Azelastine Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Baclofen The risk or severity of adverse effects can be increased when Butabarbital is combined with Baclofen. Approved Barbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Barbital. Illicit Benperidol The risk or severity of adverse effects can be increased when Butabarbital is combined with Benperidol. Approved, Investigational Benzocaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Benzocaine. Approved, Investigational Benzyl alcohol The risk or severity of adverse effects can be increased when Butabarbital is combined with Benzyl alcohol. Approved Brexpiprazole The risk or severity of adverse effects can be increased when Butabarbital is combined with Brexpiprazole. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital. Approved Bromazepam The risk or severity of adverse effects can be increased when Butabarbital is combined with Bromazepam. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Butabarbital is combined with Bromisoval. Experimental Bromperidol The risk or severity of adverse effects can be increased when Butabarbital is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Butabarbital is combined with Brompheniramine. Approved Brotizolam The risk or severity of adverse effects can be increased when Butabarbital is combined with Brotizolam. Approved, Investigational, Withdrawn Bupivacaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Bupivacaine. Approved, Investigational Buprenorphine Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Buspirone The risk or severity of adverse effects can be increased when Butabarbital is combined with Buspirone. Approved, Investigational Butacaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Butalbital. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Butabarbital is combined with Butamben. Approved Butethal The risk or severity of adverse effects can be increased when Butabarbital is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butabarbital is combined with Butorphanol. Approved, Illicit, Vet Approved Canertinib The risk or severity of adverse effects can be increased when Butabarbital is combined with Canertinib. Investigational Carbamazepine The risk or severity of adverse effects can be increased when Butabarbital is combined with Carbamazepine. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Butabarbital is combined with Carbinoxamine. Approved Carfentanil The risk or severity of adverse effects can be increased when Butabarbital is combined with Carfentanil. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Butabarbital is combined with Carisoprodol. Approved Cetirizine The risk or severity of adverse effects can be increased when Butabarbital is combined with Cetirizine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Butabarbital is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Butabarbital is combined with Chlordiazepoxide. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Butabarbital is combined with Chlormezanone. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Chloroprocaine. Approved Chlorphenamine The risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorphenamine. Approved Chlorpromazine The risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorpromazine. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorprothixene. Approved, Investigational, Withdrawn Chlorzoxazone The risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorzoxazone. Approved Cinchocaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Cinchocaine. Approved, Vet Approved Citalopram The risk or severity of adverse effects can be increased when Butabarbital is combined with Citalopram. Approved Clemastine The risk or severity of adverse effects can be increased when Butabarbital is combined with Clemastine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Butabarbital is combined with Clidinium. Approved Clobazam The risk or severity of adverse effects can be increased when Butabarbital is combined with Clobazam. Approved, Illicit clomethiazole The risk or severity of adverse effects can be increased when Butabarbital is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Butabarbital is combined with Clomipramine. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Butabarbital is combined with Clonazepam. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Butabarbital is combined with Clonidine. Approved Clopenthixol The risk or severity of adverse effects can be increased when Butabarbital is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Butabarbital is combined with Clorazepate. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Butabarbital is combined with Clothiapine. Experimental Clozapine The risk or severity of adverse effects can be increased when Butabarbital is combined with Clozapine. Approved Cocaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Cocaine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Butabarbital is combined with Codeine. Approved, Illicit Cyclizine The risk or severity of adverse effects can be increased when Butabarbital is combined with Cyclizine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Butabarbital is combined with Cyclobenzaprine. Approved Cyclopropane The risk or severity of adverse effects can be increased when Butabarbital is combined with Cyclopropane. Experimental Cyproheptadine The risk or severity of adverse effects can be increased when Butabarbital is combined with Cyproheptadine. Approved Dantrolene The risk or severity of adverse effects can be increased when Butabarbital is combined with Dantrolene. Approved, Investigational Dapiprazole The risk or severity of adverse effects can be increased when Butabarbital is combined with Dapiprazole. Approved Dapoxetine The risk or severity of adverse effects can be increased when Butabarbital is combined with Dapoxetine. Investigational Deramciclane The risk or severity of adverse effects can be increased when Butabarbital is combined with Deramciclane. Investigational Desflurane The risk or severity of adverse effects can be increased when Butabarbital is combined with Desflurane. Approved Desipramine The risk or severity of adverse effects can be increased when Butabarbital is combined with Desipramine. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Butabarbital is combined with Desloratadine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Butabarbital is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Butabarbital is combined with Detomidine. Vet Approved Deutetrabenazine The risk or severity of sedation and somnolence can be increased when Butabarbital is combined with Deutetrabenazine. Approved, Investigational Dexbrompheniramine The risk or severity of adverse effects can be increased when Butabarbital is combined with Dexbrompheniramine. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Butabarbital is combined with Dexmedetomidine. Approved, Vet Approved Dextromoramide The risk or severity of adverse effects can be increased when Butabarbital is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Butabarbital is combined with Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Butabarbital is combined with Dezocine. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Butabarbital is combined with Diazepam. Approved, Illicit, Investigational, Vet Approved Diethyl ether The risk or severity of adverse effects can be increased when Butabarbital is combined with Diethyl ether. Experimental Difenoxin The risk or severity of adverse effects can be increased when Butabarbital is combined with Difenoxin. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydrocodeine. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Butabarbital is combined with Dihydromorphine. Experimental, Illicit Dimenhydrinate The risk or severity of adverse effects can be increased when Butabarbital is combined with Dimenhydrinate. Approved Diphenhydramine The risk or severity of adverse effects can be increased when Butabarbital is combined with Diphenhydramine. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Butabarbital is combined with Diphenoxylate. Approved, Illicit Dixyrazine The risk or severity of adverse effects can be increased when Butabarbital is combined with Dixyrazine. Experimental Doramectin The risk or severity of adverse effects can be increased when Butabarbital is combined with Doramectin. Vet Approved Doxepin The risk or severity of adverse effects can be increased when Butabarbital is combined with Doxepin. Approved, Investigational Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Butabarbital is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Butabarbital. Approved, Illicit Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Butabarbital. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Butabarbital is combined with Drotebanol. Experimental, Illicit Duloxetine The risk or severity of adverse effects can be increased when Butabarbital is combined with Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Butabarbital is combined with Dyclonine. Approved Ecgonine The risk or severity of adverse effects can be increased when Butabarbital is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Butabarbital is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Butabarbital is combined with Efavirenz. Approved, Investigational Eltanolone The risk or severity of adverse effects can be increased when Butabarbital is combined with Eltanolone. Investigational Enflurane The risk or severity of adverse effects can be increased when Butabarbital is combined with Enflurane. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Butabarbital is combined with Entacapone. Approved, Investigational Escitalopram The risk or severity of adverse effects can be increased when Butabarbital is combined with Escitalopram. Approved, Investigational Estazolam The risk or severity of adverse effects can be increased when Butabarbital is combined with Estazolam. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Butabarbital is combined with Eszopiclone. Approved, Investigational Ethanol Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Butabarbital is combined with Ethchlorvynol. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Butabarbital is combined with Ethosuximide. Approved Ethotoin The risk or severity of adverse effects can be increased when Butabarbital is combined with Ethotoin. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Butabarbital is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Butabarbital is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Butabarbital is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Butabarbital is combined with Ethylmorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Butabarbital is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Butabarbital is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Butabarbital is combined with Etomidate. Approved Etoperidone The risk or severity of adverse effects can be increased when Butabarbital is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Butabarbital is combined with Etorphine. Illicit, Vet Approved Ezogabine The risk or severity of adverse effects can be increased when Butabarbital is combined with Ezogabine. Approved, Investigational Felbamate The risk or severity of adverse effects can be increased when Butabarbital is combined with Felbamate. Approved Fencamfamine The risk or severity of adverse effects can be increased when Butabarbital is combined with Fencamfamine. Approved, Illicit, Withdrawn Fentanyl The risk or severity of adverse effects can be increased when Butabarbital is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Butabarbital is combined with Fexofenadine. Approved, Investigational Flibanserin The risk or severity of adverse effects can be increased when Butabarbital is combined with Flibanserin. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Butabarbital is combined with Fluanisone. Experimental Fludiazepam The risk or severity of adverse effects can be increased when Butabarbital is combined with Fludiazepam. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Butabarbital is combined with Flunarizine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Butabarbital is combined with Flunitrazepam. Approved, Illicit Fluoxetine The risk or severity of adverse effects can be increased when Butabarbital is combined with Fluoxetine. Approved, Vet Approved Flupentixol The risk or severity of adverse effects can be increased when Butabarbital is combined with Flupentixol. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Butabarbital is combined with Fluphenazine. Approved Flurazepam The risk or severity of adverse effects can be increased when Butabarbital is combined with Flurazepam. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Butabarbital is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Butabarbital is combined with Fluticasone propionate. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Butabarbital is combined with Fluvoxamine. Approved, Investigational Fosphenytoin The risk or severity of adverse effects can be increased when Butabarbital is combined with Fosphenytoin. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Butabarbital is combined with Fospropofol. Approved, Illicit, Investigational Gabapentin The risk or severity of adverse effects can be increased when Butabarbital is combined with Gabapentin. Approved, Investigational Gabapentin Enacarbil The risk or severity of adverse effects can be increased when Butabarbital is combined with Gabapentin Enacarbil. Approved, Investigational Gamma Hydroxybutyric Acid The risk or severity of adverse effects can be increased when Butabarbital is combined with Gamma Hydroxybutyric Acid. Approved, Illicit, Investigational Gepirone The risk or severity of adverse effects can be increased when Butabarbital is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Butabarbital is combined with Glutethimide. Approved, Illicit Guanfacine The risk or severity of adverse effects can be increased when Butabarbital is combined with Guanfacine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Butabarbital is combined with Halazepam. Approved, Illicit, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Butabarbital is combined with Haloperidol. Approved Halothane The risk or severity of adverse effects can be increased when Butabarbital is combined with Halothane. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Butabarbital is combined with Heroin. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Hexobarbital. Approved Hydrocodone Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit Hydromorphone The risk or severity of adverse effects can be increased when Butabarbital is combined with Hydromorphone. Approved, Illicit Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital. Approved Iloperidone The risk or severity of adverse effects can be increased when Butabarbital is combined with Iloperidone. Approved Imipramine The risk or severity of adverse effects can be increased when Butabarbital is combined with Imipramine. Approved Indalpine The risk or severity of adverse effects can be increased when Butabarbital is combined with Indalpine. Investigational, Withdrawn Indiplon The risk or severity of adverse effects can be increased when Butabarbital is combined with Indiplon. Investigational Isoflurane The risk or severity of adverse effects can be increased when Butabarbital is combined with Isoflurane. Approved, Vet Approved Ketamine The risk or severity of adverse effects can be increased when Butabarbital is combined with Ketamine. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Butabarbital is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Butabarbital is combined with Ketobemidone. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Butabarbital is combined with Lamotrigine. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Butabarbital is combined with Levetiracetam. Approved, Investigational Levobupivacaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Levobupivacaine. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Butabarbital is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Butabarbital is combined with Levocetirizine. Approved Levodopa The risk or severity of adverse effects can be increased when Butabarbital is combined with Levodopa. Approved Levomethadyl Acetate The risk or severity of adverse effects can be increased when Butabarbital is combined with Levomethadyl Acetate. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Butabarbital is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Butabarbital is combined with Levorphanol. Approved Lidocaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Lidocaine. Approved, Vet Approved Lithium The risk or severity of adverse effects can be increased when Butabarbital is combined with Lithium. Approved Lofentanil The risk or severity of adverse effects can be increased when Butabarbital is combined with Lofentanil. Illicit Loprazolam The risk or severity of adverse effects can be increased when Butabarbital is combined with Loprazolam. Experimental Loratadine The risk or severity of adverse effects can be increased when Butabarbital is combined with Loratadine. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Butabarbital. Approved Lormetazepam The risk or severity of adverse effects can be increased when Butabarbital is combined with Lormetazepam. Approved Loxapine The risk or severity of adverse effects can be increased when Butabarbital is combined with Loxapine. Approved Lurasidone The risk or severity of adverse effects can be increased when Butabarbital is combined with Lurasidone. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Butabarbital can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Maprotiline The risk or severity of adverse effects can be increased when Butabarbital is combined with Maprotiline. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Butabarbital is combined with Mebicar. Experimental Meclizine The risk or severity of adverse effects can be increased when Butabarbital is combined with Meclizine. Approved Medazepam The risk or severity of adverse effects can be increased when Butabarbital is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Butabarbital is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Butabarbital is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Butabarbital is combined with Melperone. Approved, Investigational Mepivacaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Butabarbital is combined with Meprobamate. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Butabarbital is combined with Meptazinol. Experimental Mesoridazine The risk or severity of adverse effects can be increased when Butabarbital is combined with Mesoridazine. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Butabarbital is combined with Metaxalone. Approved Methadone The risk or severity of adverse effects can be increased when Butabarbital is combined with Methadone. Approved Methadyl Acetate The risk or severity of adverse effects can be increased when Butabarbital is combined with Methadyl Acetate. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Butabarbital is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Butabarbital is combined with Methaqualone. Illicit, Withdrawn Methocarbamol The risk or severity of adverse effects can be increased when Butabarbital is combined with Methocarbamol. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Butabarbital is combined with Methohexital. Approved Methotrimeprazine Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Butabarbital is combined with Methoxyflurane. Approved, Investigational, Vet Approved Methsuximide The risk or severity of adverse effects can be increased when Butabarbital is combined with Methsuximide. Approved Methylecgonine The risk or severity of adverse effects can be increased when Butabarbital is combined with Methylecgonine. Experimental Methylphenobarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Methylphenobarbital. Approved Metyrosine Butabarbital may increase the sedative activities of Metyrosine. Approved Midazolam The risk or severity of adverse effects can be increased when Butabarbital is combined with Midazolam. Approved, Illicit Milnacipran The risk or severity of adverse effects can be increased when Butabarbital is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Butabarbital. Approved, Investigational Mirtazapine Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Molindone The risk or severity of adverse effects can be increased when Butabarbital is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Butabarbital is combined with Morphine. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Butabarbital. Approved, Investigational Nalbuphine The risk or severity of adverse effects can be increased when Butabarbital is combined with Nalbuphine. Approved Nefazodone The risk or severity of adverse effects can be increased when Butabarbital is combined with Nefazodone. Approved, Withdrawn Nitrazepam The risk or severity of adverse effects can be increased when Butabarbital is combined with Nitrazepam. Approved Nitrous oxide The risk or severity of adverse effects can be increased when Butabarbital is combined with Nitrous oxide. Approved, Vet Approved Norflurane The risk or severity of adverse effects can be increased when Butabarbital is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Butabarbital is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Butabarbital is combined with Nortriptyline. Approved Olanzapine The risk or severity of adverse effects can be increased when Butabarbital is combined with Olanzapine. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Butabarbital is combined with Olopatadine. Approved Ondansetron The risk or severity of adverse effects can be increased when Butabarbital is combined with Ondansetron. Approved Opium The risk or severity of adverse effects can be increased when Butabarbital is combined with Opium. Approved, Illicit Orphenadrine Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Butabarbital is combined with Osanetant. Investigational Oxazepam The risk or severity of adverse effects can be increased when Butabarbital is combined with Oxazepam. Approved Oxethazaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Oxethazaine. Approved, Investigational Oxprenolol The risk or severity of adverse effects can be increased when Butabarbital is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Oxybuprocaine. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Butabarbital is combined with Oxycodone. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Butabarbital is combined with Oxymorphone. Approved, Investigational, Vet Approved Paliperidone The risk or severity of adverse effects can be increased when Butabarbital is combined with Paliperidone. Approved Paraldehyde Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Butabarbital is combined with Paroxetine. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Butabarbital is combined with Penfluridol. Experimental Pentazocine The risk or severity of adverse effects can be increased when Butabarbital is combined with Pentazocine. Approved, Vet Approved Pentobarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Pentobarbital. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Butabarbital. Approved Perazine The risk or severity of adverse effects can be increased when Butabarbital is combined with Perazine. Approved, Investigational Perospirone The risk or severity of adverse effects can be increased when Butabarbital is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Butabarbital is combined with Perphenazine. Approved Pethidine The risk or severity of adverse effects can be increased when Butabarbital is combined with Pethidine. Approved Phenazocine The risk or severity of adverse effects can be increased when Butabarbital is combined with Phenazocine. Experimental Phenibut The risk or severity of adverse effects can be increased when Butabarbital is combined with Phenibut. Experimental Phenobarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Phenobarbital. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Butabarbital is combined with Phenoperidine. Experimental Phenoxyethanol The risk or severity of adverse effects can be increased when Butabarbital is combined with Phenoxyethanol. Approved Phenytoin The risk or severity of adverse effects can be increased when Butabarbital is combined with Phenytoin. Approved, Vet Approved Pimozide The risk or severity of adverse effects can be increased when Butabarbital is combined with Pimozide. Approved Pipamperone The risk or severity of adverse effects can be increased when Butabarbital is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Butabarbital is combined with Pipotiazine. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Butabarbital is combined with Piritramide. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Butabarbital is combined with Pizotifen. Approved Pomalidomide The risk or severity of adverse effects can be increased when Butabarbital is combined with Pomalidomide. Approved Pramipexole Butabarbital may increase the sedative activities of Pramipexole. Approved, Investigational Pramocaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Pramocaine. Approved Prazepam The risk or severity of adverse effects can be increased when Butabarbital is combined with Prazepam. Approved, Illicit Pregabalin The therapeutic efficacy of Butabarbital can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Prilocaine. Approved Primidone The risk or severity of adverse effects can be increased when Butabarbital is combined with Primidone. Approved, Vet Approved Procaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Procaine. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Butabarbital is combined with Prochlorperazine. Approved, Vet Approved Promazine The risk or severity of adverse effects can be increased when Butabarbital is combined with Promazine. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Butabarbital is combined with Promethazine. Approved, Investigational Propanidid The risk or severity of adverse effects can be increased when Butabarbital is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Proparacaine. Approved, Vet Approved Propofol The risk or severity of adverse effects can be increased when Butabarbital is combined with Propofol. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Propoxycaine. Approved Protriptyline The risk or severity of adverse effects can be increased when Butabarbital is combined with Protriptyline. Approved Proxibarbal The risk or severity of adverse effects can be increased when Butabarbital is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Butabarbital is combined with PSD502. Investigational Quazepam The risk or severity of adverse effects can be increased when Butabarbital is combined with Quazepam. Approved, Illicit Quetiapine The risk or severity of adverse effects can be increased when Butabarbital is combined with Quetiapine. Approved Quinisocaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Butabarbital is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Butabarbital is combined with Ramelteon. Approved, Investigational Remifentanil The risk or severity of adverse effects can be increased when Butabarbital is combined with Remifentanil. Approved Remoxipride The risk or severity of adverse effects can be increased when Butabarbital is combined with Remoxipride. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Butabarbital. Approved, Investigational Risperidone The risk or severity of adverse effects can be increased when Butabarbital is combined with Risperidone. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Butabarbital is combined with Ritanserin. Investigational Romifidine The risk or severity of adverse effects can be increased when Butabarbital is combined with Romifidine. Vet Approved Ropinirole Butabarbital may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Ropivacaine. Approved Rotigotine Butabarbital may increase the sedative activities of Rotigotine. Approved Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Butabarbital. Approved Scopolamine The risk or severity of adverse effects can be increased when Butabarbital is combined with Scopolamine. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Secobarbital. Approved, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Butabarbital is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Butabarbital is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Butabarbital is combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Butabarbital is combined with Sevoflurane. Approved, Vet Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Butabarbital. Approved Stiripentol The risk or severity of adverse effects can be increased when Butabarbital is combined with Stiripentol. Approved Sufentanil The risk or severity of adverse effects can be increased when Butabarbital is combined with Sufentanil. Approved, Investigational Sulpiride The risk or severity of adverse effects can be increased when Butabarbital is combined with Sulpiride. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Butabarbital is combined with Sultopride. Experimental Suvorexant Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Butabarbital is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Butabarbital. Approved Tasimelteon The risk or severity of adverse effects can be increased when Butabarbital is combined with Tasimelteon. Approved, Investigational Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Butabarbital. Approved, Investigational Tetrabenazine The risk or severity of adverse effects can be increased when Butabarbital is combined with Tetrabenazine. Approved, Investigational Tetracaine The risk or severity of adverse effects can be increased when Butabarbital is combined with Tetracaine. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Butabarbital is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Butabarbital is combined with Tetrodotoxin. Investigational Thalidomide Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Thiamylal The risk or severity of adverse effects can be increased when Butabarbital is combined with Thiamylal. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Butabarbital is combined with Thiopental. Approved, Vet Approved Thioridazine The risk or severity of adverse effects can be increased when Butabarbital is combined with Thioridazine. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Butabarbital is combined with Thiothixene. Approved Tiagabine The risk or severity of adverse effects can be increased when Butabarbital is combined with Tiagabine. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Butabarbital is combined with Tiapride. Approved, Investigational Tiletamine The risk or severity of adverse effects can be increased when Butabarbital is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Butabarbital is combined with Tilidine. Experimental Tizanidine The risk or severity of adverse effects can be increased when Butabarbital is combined with Tizanidine. Approved, Investigational Tolcapone The risk or severity of adverse effects can be increased when Butabarbital is combined with Tolcapone. Approved, Withdrawn Topiramate The risk or severity of adverse effects can be increased when Butabarbital is combined with Topiramate. Approved Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Butabarbital. Approved, Investigational Tranylcypromine The risk or severity of adverse effects can be increased when Butabarbital is combined with Tranylcypromine. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Butabarbital is combined with Trazodone. Approved, Investigational Triazolam The risk or severity of adverse effects can be increased when Butabarbital is combined with Triazolam. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Butabarbital is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Butabarbital is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Butabarbital is combined with Trifluoperazine. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Butabarbital is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Butabarbital is combined with Triflupromazine. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Butabarbital is combined with Trimipramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Butabarbital is combined with Triprolidine. Approved Valproic Acid The risk or severity of adverse effects can be increased when Butabarbital is combined with Valproic Acid. Approved, Investigational Venlafaxine The risk or severity of adverse effects can be increased when Butabarbital is combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Butabarbital is combined with Veralipride. Experimental Vigabatrin The risk or severity of adverse effects can be increased when Butabarbital is combined with Vigabatrin. Approved Vinyl ether The risk or severity of adverse effects can be increased when Butabarbital is combined with Vinyl ether. Experimental Vortioxetine The risk or severity of adverse effects can be increased when Butabarbital is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Butabarbital is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Butabarbital is combined with Xylazine. Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Butabarbital is combined with Zaleplon. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Butabarbital is combined with Ziconotide. Approved Zimelidine The risk or severity of adverse effects can be increased when Butabarbital is combined with Zimelidine. Withdrawn Ziprasidone The risk or severity of adverse effects can be increased when Butabarbital is combined with Ziprasidone. Approved Zolazepam The risk or severity of adverse effects can be increased when Butabarbital is combined with Zolazepam. Vet Approved Zolpidem Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Butabarbital is combined with Zonisamide. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Butabarbital is combined with Zopiclone. Approved Zotepine The risk or severity of adverse effects can be increased when Butabarbital is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol The risk or severity of adverse effects can be increased when Butabarbital is combined with Zuclopenthixol. Approved, Investigational - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014382
- KEGG Drug
- D03180
- KEGG Compound
- C07827
- PubChem Compound
- 2479
- PubChem Substance
- 46505051
- ChemSpider
- 2385
- ChEBI
- 3228
- ChEMBL
- CHEMBL449
- Therapeutic Targets Database
- DAP000667
- PharmGKB
- PA164743463
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Butabarbital
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Medpointe pharmaceuticals medpointe healthcare inc
- Alpharma us pharmaceuticals division
- Wockhardt eu operations (swiss) ag
- Lannett co inc
- Meda pharmaceuticals inc
- Halsey drug co inc
- Cm bundy co
- Sandoz inc
- Solvay pharmaceuticals
- Teva pharmaceuticals usa inc
- Watson laboratories inc
- Whiteworth towne paulsen inc
- Ivax pharmaceuticals inc sub teva pharmaceuticals usa
- Marshall pharmacal corp
- West ward pharmaceutical corp
- Packagers
- C.O. Truxton Inc.
- Chattem Chemicals Inc.
- Meda AB
- Dosage forms
Form Route Strength Tablet Oral 30 mg/1 Tablet Oral 100 mg Tablet Oral 15 mg Tablet Oral 30 mg - Prices
Unit description Cost Unit Butisol sodium 50 mg tablet 2.46USD tablet Butisol sodium 30 mg tablet 1.89USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 166.5 °C PhysProp water solubility 1360 mg/L Not Available logP 1.65 WONG,O & MCKEOWN,RH (1988) - Predicted Properties
Property Value Source Water Solubility 1.39 mg/mL ALOGPS logP 1.7 ALOGPS logP 1.45 ChemAxon logS -2.2 ALOGPS pKa (Strongest Acidic) 8.48 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 75.27 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 53.4 m3·mol-1 ChemAxon Polarizability 21.41 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9324 Blood Brain Barrier + 0.9782 Caco-2 permeable - 0.6013 P-glycoprotein substrate Substrate 0.5938 P-glycoprotein inhibitor I Non-inhibitor 0.617 P-glycoprotein inhibitor II Non-inhibitor 0.961 Renal organic cation transporter Non-inhibitor 0.9465 CYP450 2C9 substrate Non-substrate 0.7719 CYP450 2D6 substrate Non-substrate 0.9014 CYP450 3A4 substrate Non-substrate 0.7098 CYP450 1A2 substrate Non-inhibitor 0.8775 CYP450 2C9 inhibitor Non-inhibitor 0.821 CYP450 2D6 inhibitor Non-inhibitor 0.933 CYP450 2C19 inhibitor Non-inhibitor 0.7828 CYP450 3A4 inhibitor Non-inhibitor 0.9203 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9458 Ames test Non AMES toxic 0.6458 Carcinogenicity Non-carcinogens 0.8533 Biodegradation Not ready biodegradable 0.9759 Rat acute toxicity 3.6803 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.99 hERG inhibition (predictor II) Non-inhibitor 0.9233
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Mass Spectrum (Electron Ionization) MS splash10-0a4l-6900000000-6e0cbc3d26c5541ad8eb Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazines
- Sub Class
- Pyrimidines and pyrimidine derivatives
- Direct Parent
- Barbituric acid derivatives
- Alternative Parents
- N-acyl ureas / Diazinanes / Dicarboximides / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Barbiturate / N-acyl urea / Ureide / 1,3-diazinane / Dicarboximide / Urea / Carbonic acid derivative / Carboxylic acid derivative / Azacycle / Organic nitrogen compound
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- barbiturates (CHEBI:3228)
Targets
- Kind
- Protein group
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Positive allosteric modulator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Components:
References
- Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
- Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Ligand-gated ion channel activity
- Specific Function
- After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
- Gene Name
- CHRNA4
- Uniprot ID
- P43681
- Uniprot Name
- Neuronal acetylcholine receptor subunit alpha-4
- Molecular Weight
- 69956.47 Da
References
- Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
- Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797]
- Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Toxic substance binding
- Specific Function
- After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The cha...
- Gene Name
- CHRNA7
- Uniprot ID
- P36544
- Uniprot Name
- Neuronal acetylcholine receptor subunit alpha-7
- Molecular Weight
- 56448.925 Da
References
- Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
- Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797]
- Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Ionotropic glutamate receptor activity
- Specific Function
- Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory ne...
- Gene Name
- GRIA2
- Uniprot ID
- P42262
- Uniprot Name
- Glutamate receptor 2
- Molecular Weight
- 98820.32 Da
References
- Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
- Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Kainate selective glutamate receptor activity
- Specific Function
- Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a co...
- Gene Name
- GRIK2
- Uniprot ID
- Q13002
- Uniprot Name
- Glutamate receptor ionotropic, kainate 2
- Molecular Weight
- 102582.475 Da
References
- Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
- Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Drug created on June 13, 2005 07:24 / Updated on March 02, 2018 05:06